1. Home
  2. ALT vs EMX Comparison

ALT vs EMX Comparison

Compare ALT & EMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • EMX
  • Stock Information
  • Founded
  • ALT 1997
  • EMX N/A
  • Country
  • ALT United States
  • EMX Canada
  • Employees
  • ALT N/A
  • EMX N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • EMX
  • Sector
  • ALT Health Care
  • EMX
  • Exchange
  • ALT Nasdaq
  • EMX Nasdaq
  • Market Cap
  • ALT 292.0M
  • EMX 338.0M
  • IPO Year
  • ALT N/A
  • EMX N/A
  • Fundamental
  • Price
  • ALT $3.83
  • EMX $3.65
  • Analyst Decision
  • ALT Strong Buy
  • EMX Strong Buy
  • Analyst Count
  • ALT 6
  • EMX 2
  • Target Price
  • ALT $17.40
  • EMX $5.38
  • AVG Volume (30 Days)
  • ALT 3.0M
  • EMX 447.8K
  • Earning Date
  • ALT 08-12-2025
  • EMX 08-11-2025
  • Dividend Yield
  • ALT N/A
  • EMX N/A
  • EPS Growth
  • ALT N/A
  • EMX N/A
  • EPS
  • ALT N/A
  • EMX 0.04
  • Revenue
  • ALT $20,000.00
  • EMX $29,864,000.00
  • Revenue This Year
  • ALT N/A
  • EMX $11.08
  • Revenue Next Year
  • ALT $761,880.20
  • EMX $3.72
  • P/E Ratio
  • ALT N/A
  • EMX $80.97
  • Revenue Growth
  • ALT N/A
  • EMX N/A
  • 52 Week Low
  • ALT $2.90
  • EMX $1.59
  • 52 Week High
  • ALT $11.16
  • EMX $3.66
  • Technical
  • Relative Strength Index (RSI)
  • ALT 51.79
  • EMX 74.62
  • Support Level
  • ALT $3.35
  • EMX $3.04
  • Resistance Level
  • ALT $3.66
  • EMX $3.37
  • Average True Range (ATR)
  • ALT 0.19
  • EMX 0.12
  • MACD
  • ALT 0.07
  • EMX 0.03
  • Stochastic Oscillator
  • ALT 86.18
  • EMX 97.58

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About EMX EMX Royalty Corporation (Canada)

EMX Royalty Corp and its subsidiaries operate as a royalty and prospect generator engaged in exploring for and generating royalties from, metals and minerals properties. The company is a precious, and base metals royalty company. The Company augments royalty generation with royalty acquisitions and strategic investments. EMX's royalty and mineral property portfolio consists of properties in North America, Europe, Turkiye, Latin America, Morocco and Australia.

Share on Social Networks: